COMBINED TREATMENT OF A PATIENT WITH A TESTICULAR GERM CELL TUMOR WITH SIGNS OF MULTIPLE ORGAN FAILURE

Testicular cancer is a rare malignant tumor. In the structure of general cancer incidence, this nosology accounts for about 1–1.5% of cases. Among this pathology, about 90–95% is due to testicular germ cell tumors. Currently, testicular cancer is a potentially treatable solid tumor with a 10-year survival rate of more than 95% upon timely diagnosis and proper treatment. In this regard, early diagnosis and treatment of this pathology is an urgent task today. The article presents a clinical observation of the treatment of a patient with a testicular germ cell tumor. The presented clinical case demonstrates the successful conduct of neoadjuvant chemotherapy and further orchifuniculectomy in the presence of distant metastases namely in case of a non-seminomic form of a testicular germ cell tumor. The approach to treating patients with testicular tumors must be individualized and take into account both the potential gain and the potential risks of the treatment being performed.

1. Chia VM, Quraishi SM, Devesa SS, Purdue MP, Cook MB, McGlynn KA. International trends in the incidence of testicular cancer, 1973–2002. Cancer Epidemiol Biomarkers Prev. 2010 May;19 (5):1151–9. DOI: 10.1158/1055–9965.EPI-10–0031

2. Boccellino M, Vanacore D, Zappavigna S, Cavaliere C, Rossetti S, D’Aniello C, et al. Testicular cancer from diagnosis to epigenetic factors. Oncotarget. 2017 Sep 18;8 (61):104654–104663. DOI: 10.18632/oncotarget.20992

3. Malignant neoplasms in Russia in 2017. Edited by A. D. Kaprin, V. V. Starinskii, G. V. Petrova. Мoscow: P. Hertsen Moscow Oncology Research Institute — Branch of the National Medical Radiology Research Centre of the Ministry of Health of the Russian Federation; 2018, 250 p. Available at: http://www.oncology. ru/service/statistics/malignant_tumors/2017.pdf (In Russian).

4. Verdecchia A, Francisci S, Brenner H, Gatta G, Micheli A, Mangone L, et al. Recent cancer survival in Europe: a 2000–02 period analysis of EUROCARE-4 data. Lancet Oncol. 2007 Sep;8 (9):784–96. DOI: 10.1016/S1470–2045 (07)70246–2

5. Masters J, Köberle B. Curing metastatic cancer: lessons from testicular germ-cell tumours. Nat Rev Cancer. 2003 Jul;3 (7):517–25. DOI: 10.1038/nrc1120

6. Simmonds PD, Mead GM, Lee AH, Theaker JM, Dewbury K, Smart CJ. Orchiectomy after chemotherapy in рatients with metastatic testicular cancer. Is it indicated? Cancer. 1995 Feb 15;75 (4):1018–24. DOI: 10.1002/1097–0142 (19950215)75:43.0.co;2-y

7. Ondrus D, Hornák M, Breza J, Mat’oska J, Schnorrer M, Belan V, Kausitz J. Delayed orchiectomy after chemotherapy in patients with advanced testicular cancer. Int Urol Nephrol. 2001;32 (4):665–7.

8. Geldart TR, Simmonds PD, Mead GM. Orchidectomy after chemotherapy for patients with metastatic testicular germ cell cancer. BJU Int. 2002 Sep;90 (4):451–5.

9. Ramani VA, Grey BR, Addla SK, Dunham MP, Sangar VK, Clarke NW. Histological Outcome of Delayed Orchidectomy after Primary Chemotherapy for Metastatic Germ Cell Tumour of the Testis. Clin Oncol (R Coll Radiol). 2008 Apr;20 (3):247–52. DOI: 10.1016/j. clon.2007.11.009

10. Tryakin AA, Fedyanin MY, Bulanov AA, Matveev VB, Sergeev JuS, Fainstein IA, et al. Treatment of patients with poor risk nonseminomatous germ cell tumors at advanced stages. Malignant Tumoursis. 2017;7 (3):23–30. DOI: 10.18027/2224– 5057–2017–7-3–23–29 (In Russian).